dimethylbiguanide hydrochloride
GPTKB entity
Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:alternativeName |
metformin hydrochloride
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A10BA02
|
| gptkbp:belongs_to_class |
gptkb:biguanides
|
| gptkbp:CASNumber |
1115-70-4
|
| gptkbp:contraindication |
renal impairment
severe liver disease |
| gptkbp:discoveredBy |
1922
|
| gptkbp:eliminationHalfLife |
4-8.7 hours
|
| gptkbp:excretion |
kidneys
|
| gptkbp:hasMolecularFormula |
C4H12ClN5
|
| gptkbp:hasUNII |
9100L32L2N
|
| https://www.w3.org/2000/01/rdf-schema#label |
dimethylbiguanide hydrochloride
|
| gptkbp:IUPACName |
gptkb:1,1-dimethylbiguanide_hydrochloride
|
| gptkbp:mechanismOfAction |
increases insulin sensitivity
reduces hepatic glucose production |
| gptkbp:meltingPoint |
223-226°C
|
| gptkbp:molecularWeight |
165.66 g/mol
|
| gptkbp:PubChem_CID |
4091
DB00331 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gastrointestinal upset
lactic acidosis |
| gptkbp:usedFor |
gptkb:type_2_diabetes
antidiabetic medication |
| gptkbp:bfsParent |
gptkb:Metformin_HCl
|
| gptkbp:bfsLayer |
8
|